Physician profile
Talha Badar
NPI 1760818959
$35,626.27
in general payments reported to CMS, 2019-2025
13 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $216 · 2021: $5,250 · 2022: $55.00 · 2023: $11K · 2024: $1,482 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $24K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,700 · Travel and Lodging: $1,283 · Food and Beverage: $1,016 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,144.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,700.00 |
| Travel and Lodging | $1,283.46 |
| Food and Beverage | $1,015.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $8,752.19 | 2025 | Revuforj |
| Takeda Pharmaceuticals U.S.A., INC. | $8,722.32 | 2023-2025 | Iclusig |
| Pfizer INC. | $8,090.98 | 2021-2023 | |
| Morphosys, US INC. | $3,913.94 | 2023 | |
| Amgen INC. | $2,191.35 | 2025 | Blincyto |
| Astrazeneca Pharmaceuticals LP | $1,424.08 | 2019-2024 | Calquence |
| Celgene Corporation | $712.88 | 2019-2023 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Sobi, INC | $200.00 | 2024 | |
| Gilead Sciences, INC. | $147.59 | 2025 | Trodelvy |
| Janssen Biotech, INC. | $90.94 | 2020 | |
| Astrazeneca Uk Limited | $55.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talha Badar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.